Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Korábbi kezelés

• Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of first administration.
• History of stroke or intracranial haemorrhage within 6 months before the first administration.
• Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of DZD9008.

Más betegség

• Known history of bleeding diathesis.
• Prior malignancy within 2 years requires active treatment.
• As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
• Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
• History of hypersensitivity to active or inactive excipients of DZD9008 or drugs with a similar chemical structure or class to DZD9008.

Laborértékek

• Any of the following cardiac criteria:
  • Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs);
  • Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec.
  • Any factors that increase the risk of QTcF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
  • Prior history of atrial fibrillation within 6 months of first administration of DZD9008, except prior drug treatment related and recovered.

Egyéb

• Spinal cord compression or leptomeningeal metastasis.
• Women who are pregnant or breast feeding.
• Involvement in the planning and conduct of the study.
• Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

• To provide a signed and dated, written informed consent.
• Aged ≥ 18 years old
• Histologically or cytologically confirmed locally advanced or metastatic NSCLC with documented EGFR mutations from a local laboratory
• ECOG performance status 0-1.
• Predicted life expectancy ≥ 12 weeks
• Patient must have measurable disease according to RECIST 1.1.
• Patient who has progressed or intolerant to standard therapy (except treatment naïve patients in Cohort 4 and Cohort 7: with EGFR Exon20ins; in Cohort 5 with EGFR sensitizing mutation; and in Cohort8 with EGFR PACC mutation).
• Patients with brain metastasis (BM) can be enrolled under the condition that BM is stable, neurologically asymptomatic and does not require corticosteroid treatment.
• Adequate organ system function.
  • Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
  • Platelets ≥ 100 x 10\^9/L
  • Hemoglobin ≥ 9 g/dL
  • Total bilirubin ≤ 1.5 x ULN if no liver metastases or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN if no liver metastases or ≤ 5 x ULN with liver metastases
  • Creatinine ≤ 1.5 x ULN, concurrent with calculated or measured creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault method or ≥ 50 mL/min in 24 hours
  • International normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;
  • Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN